How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?  

If I see a patient with new metastatic NSCLC with limited/no next-generation sequencing (NGS) testing, I will attempt to initiate testing in some way while formulating a treatment plan. Specifically, I will either attempt to do tumor based NGS if feasible and timely (goal for getting results back in...

Many commercial test vendors generally host their own online "portal" for results with a search function thus it is helpful to create an account, some of which can also be enabled to permit administrative personnel to centrally manage all incoming results for a group practice. Thus, if the ordering ...

This is a great question and comes up often. I tend to do liquid biopsy right then and there and order the tissue re-biopsy if there is a lesion that would be amenable for a biopsy. If we are lucky and there are positive liquid biopsy results, I might cancel the tissue biopsy but I do think that eve...

I agree this is a great question and I agree with what had already been said- the only point I would add is the importance of recognizing what it means for mutation testing to be 'insufficient'.  I believe this is not only in cases where a few genes were tested, but also in cases where liquid ...